Diadema Partners’s Aprea Therapeutics APRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$21.7K Sell
28,872
-16,035
-36% -$11.6K ﹤0.01% 138
2026
Q2
$36K Buy
+44,907
New +$37.5K ﹤0.01% 141

Other funds holding APRE

Diadema Partners's APRE Position: Q3 2026 in Review

Diadema Partners reduced its Aprea Therapeutics (APRE) stake by 36% in Q3 2026, selling an estimated $11.6K and leaving 28,872 shares worth $21.7K. The position accounts for ﹤0.01% of the portfolio, ranked #138.

Diadema Partners first reported a position in APRE in Q2 2026 and has held it in 2 quarters since. The position peaked at $36K in Q2 2026. 28 funds tracked by Wall St. Rank hold APRE as of Q3 2026.

  • Diadema Partners held 28,872 shares of Aprea Therapeutics worth $21.7K as of Q3 2026.
  • Diadema Partners sold 16,035 Aprea Therapeutics shares in Q3 2026, an estimated $11.6K.
  • Aprea Therapeutics made up ﹤0.01% of Diadema Partners's portfolio in Q3 2026, its #138 holding.
  • Diadema Partners first reported a position in Aprea Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Diadema Partners's Aprea Therapeutics position peaked at $36K in Q2 2026.
  • 28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2026.

Based on Diadema Partners's 13F filing for Q3 2026, filed 16 Nov 2026.